| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| PLRZPolyrizon Ltd. | 16.19M | 15.54 | 31.08 | -5.21% | ||||
| TOVXTheriva Biologics, Inc. | 7.49M | 0.21 | -0.01 | -388.69% | 0.08 | |||
| CTXRCitius Pharmaceuticals, Inc. | 17.79M | 0.86 | -0.14 | -258.23% | -59.6% | 0.00 | ||
| ACXPAcurx Pharmaceuticals, Inc. | 6.32M | 2.69 | -0.15 | -0.25% | ||||
| ITRMIterum Therapeutics plc | 17.16M | 0.32 | -0.26 | -69.13% | ||||
| ANTXAN2 Therapeutics, Inc. | 34.25M | 1.25 | -0.73 | -56.29% | ||||
| MCRBSeres Therapeutics, Inc. | 137.33M | 15.18 | -0.80 | 15.37% | 12.34% | 6.65 | ||
| PYPDPolyPid Ltd. | 73.03M | 4.39 | -0.89 | -10.39% | 1.25 |
| Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.28M | 2.88M | 17.5M | 56.41M | 611.87K | 860K | 1.81M | 704.29K | 0 | 0 |
| Revenue Growth % | -0.44% | 1.25% | 5.07% | 2.22% | -0.99% | 0.41% | 1.1% | -0.61% | -1% | - |
| Cost of Goods Sold | 0 | 0 | 97.67K | 24.92K | 155.4K | 0 | 0 | 2.51M | 2.05M | 15.01M |
| COGS % of Revenue | - | - | 0.01% | 0% | 0.25% | - | - | 3.57% | - | - |
| Gross Profit | 0 | 2.88M | 17.4M | 56.39M | 476.62K | 860K | 1.81M | -1.81M | -2.05M | -15.01M |
| Gross Margin % | - | 1% | 0.99% | 1% | 0.78% | 1% | 1% | -2.57% | - | - |
| Gross Profit Growth % | -1% | - | 5.04% | 2.24% | -0.99% | 0.8% | 1.1% | -2% | -0.13% | -6.32% |
| Operating Expenses | 29.45M | 33.95M | 54.13M | 47.69M | 39.18M | 53.19M | 88M | 64.28M | 87.69M | 211.3M |
| OpEx % of Revenue | 22.99% | 11.79% | 3.09% | 0.85% | 64.04% | 61.85% | 48.64% | 91.27% | - | - |
| Selling, General & Admin | 7.45M | 9.62M | 13.71M | 17.01M | 9.3M | 19.23M | 23.61M | 26.7M | 30.27M | 60.53M |
| SG&A % of Revenue | 5.82% | 3.34% | 0.78% | 0.3% | 15.2% | 22.36% | 13.05% | 37.91% | - | - |
| Research & Development | 23.94M | 23.69M | 41.01M | 51.38M | 39.18M | 53.27M | 85.35M | 52M | 59.47M | 150.78M |
| R&D % of Revenue | 18.69% | 8.23% | 2.34% | 0.91% | 64.04% | 61.95% | 47.18% | 73.83% | - | - |
| Other Operating Expenses | -3.14M | 639.98K | -743K | -14.41M | -18.84M | -13.49M | -20.97M | -5.95M | 0 | 0 |
| Operating Income | -28.73M | -31.07M | -36.56M | 5.39M | -22.62M | -53.19M | -86.19M | -59.63M | -89.74M | 313K |
| Operating Margin % | -22.43% | -10.79% | -2.09% | 0.1% | -36.98% | -61.85% | -47.64% | -84.67% | - | - |
| Operating Income Growth % | -0.5% | -0.08% | -0.18% | 1.15% | -5.2% | -1.35% | -0.62% | 0.31% | -0.5% | 1% |
| EBITDA | -28.67M | -30.99M | -36.21M | 7.34M | -21.23M | -51.19M | -83.73M | -58.37M | -89.58M | 17.46M |
| EBITDA Margin % | -22.38% | -10.76% | -2.07% | 0.13% | -34.7% | -59.52% | -46.29% | -82.88% | - | - |
| EBITDA Growth % | -0.5% | -0.08% | -0.17% | 1.2% | -3.89% | -1.41% | -0.64% | 0.3% | -0.53% | 1.19% |
| D&A (Non-Cash Add-back) | 68.36K | 72.5K | 348.2K | 1.95M | 1.39M | 2M | 2.46M | 1.26M | 155.32K | 17.15M |
| EBIT | -20.35M | -31.05M | -32.76M | 9.7M | -22.62M | -52.66M | -88.36M | -74.38M | -69.61M | -230M |
| Net Interest Income | 30K | -1.07M | 2.7M | -615K | -36.18K | -251K | -242K | -2.89M | -6.06M | 4.78M |
| Interest Income | 30K | 10K | 4.38M | 5K | 4.34K | 4K | 178.95K | 1.51M | 10.4M | 13.47M |
| Interest Expense | 0 | 1.08M | 1.65M | 620K | 32.52K | 255K | 281K | 4.4M | 16.46M | 8.69M |
| Other Income/Expense | -2.85M | -1.07M | 1.91M | 3.69M | -10.16M | 206.94K | -2.42M | -6.69M | -526.14M | -221.63M |
| Pretax Income | -23.2M | -32.13M | -33.86M | 9.08M | -28.41M | -52.91M | -88.6M | -78.78M | -615.87M | -221.31M |
| Pretax Margin % | -18.11% | -11.16% | -1.94% | 0.16% | -46.43% | -61.52% | -48.98% | -111.86% | - | - |
| Income Tax | -4.36M | -5.42M | -5.33M | -1.79M | -4.52M | -213K | 0 | 0 | -946K | 0 |
| Effective Tax Rate % | 1.05% | 0.67% | 0.84% | 1.09% | 0.84% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -24.34M | -21.37M | -28.53M | 9.87M | -23.88M | -52.7M | -88.6M | -78.78M | -614.93M | -221.31M |
| Net Margin % | -19% | -7.42% | -1.63% | 0.17% | -39.03% | -61.28% | -48.98% | -111.86% | - | - |
| Net Income Growth % | -0.42% | 0.12% | -0.34% | 1.35% | -3.42% | -1.21% | -0.68% | 0.11% | -6.81% | 0.64% |
| Net Income (Continuing) | -20.14M | -26.71M | -20.16M | 10.87M | -23.99M | -52.7M | -88.6M | -78.78M | -614.93M | -221.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.41 | -0.43 | -0.15 | 0.11 | -0.15 | -0.76 | -0.96 | -0.38 | -0.99 | -0.31 |
| EPS Growth % | 0.05% | -0.05% | 0.65% | 1.73% | -2.36% | -4.07% | -0.26% | 0.6% | -1.61% | 0.69% |
| EPS (Basic) | -0.41 | -0.43 | -0.16 | 0.11 | -0.15 | -0.76 | -0.96 | -0.41 | -0.99 | -0.31 |
| Diluted Shares Outstanding | 59.1M | 61.55M | 65.43M | 86.14M | 32.83M | 69.52M | 92.24M | 193.34M | 619.65M | 718.54M |
| Basic Shares Outstanding | 59.1M | 61.55M | 65.03M | 86.14M | 32.73M | 69.52M | 92.24M | 193.34M | 619.65M | 718.54M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 29.7M | 41.67M | 50.8M | 61.29M | 62.11M | 66.42M | 97.31M | 656.71M | 189.71M | 423.75M |
| Cash & Short-Term Investments | 23.22M | 35.08M | 28.45M | 35.23M | 49.96M | 66.42M | 71.79M | 348.61M | 186.24M | 412.35M |
| Cash Only | 23.22M | 35.08M | 28.45M | 35.23M | 49.96M | 66.42M | 71.79M | 348.61M | 71.42M | 104.86M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 114.82M | 307.49M |
| Accounts Receivable | 2.28M | 0 | 11.09M | 7.95M | 5.29M | 10.19M | 24.32M | 6.12M | 848K | 557K |
| Days Sales Outstanding | 649.98 | - | 231.31 | 51.41 | 3.16K | 4.32K | 4.91K | 3.17K | - | - |
| Inventory | 563.1K | 110.56K | 0 | 0 | 2 | -11.71M | 7.16M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | 0 | - | - | - | - | - |
| Other Current Assets | 4.74M | 4.59M | 15.78M | 8.3M | 6.86M | 1.52M | 1.2M | 300.49M | 181K | 10.84M |
| Total Non-Current Assets | 6.01M | 5.31M | 25.58M | 17.09M | 13.34M | 36.08M | 16.06M | 7.46M | 13.24M | 11.81M |
| Property, Plant & Equipment | 118.21K | 144.99K | 1.15M | 807.92K | 1.2M | 1.28M | 3.48M | 5.08M | 6.06M | 7.4M |
| Fixed Asset Turnover | 10.84x | 19.86x | 15.28x | 69.82x | 0.51x | 0.67x | 0.52x | 0.14x | - | - |
| Goodwill | 945.67K | 829.97K | 3.51M | 2.38M | 1.87M | 2.03M | 2.01M | 1.8M | 1.89M | 1.86M |
| Intangible Assets | 4.95M | 4.34M | 20.93M | 13.91M | 7.71M | 11.52M | 10.4M | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 3.27M | 21.26M | 170K | 577K | 5.28M | 2.55M |
| Total Assets | 35.71M | 46.98M | 76.38M | 78.39M | 75.46M | 102.5M | 113.37M | 664.17M | 202.95M | 435.56M |
| Asset Turnover | 0.04x | 0.06x | 0.23x | 0.72x | 0.01x | 0.01x | 0.02x | 0.00x | - | - |
| Asset Growth % | 0.22% | 0.32% | 0.63% | 0.03% | -0.04% | 0.36% | 0.11% | 4.86% | -0.69% | 1.15% |
| Total Current Liabilities | 4.57M | 13.62M | 26.81M | 16.88M | 9.9M | 19.89M | 25.62M | 38.78M | 20.41M | 41.73M |
| Accounts Payable | 1.02M | 1.13M | 12.49M | 5.8M | 2.63M | 6.14M | 4.37M | 355K | 2.67M | 4.64M |
| Days Payables Outstanding | - | - | 46.68K | 84.95K | 6.18K | - | - | 51.54 | 474.86 | 112.76 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 632.64K | 0 | 284.24K | 19.77M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1000K | -1000K | 0 | 1000K | 1000K | 1000K | 0 | 0 | 0 |
| Other Current Liabilities | 3.29M | 6.64M | 20.04M | 10.62M | 2.45M | 1.71M | 5.31M | 6.3M | 9.5M | 33.33M |
| Current Ratio | 6.51x | 3.06x | 1.89x | 3.63x | 6.27x | 3.34x | 3.80x | 16.93x | 9.30x | 10.15x |
| Quick Ratio | 6.38x | 3.05x | 1.89x | 3.63x | 6.27x | 3.93x | 3.52x | 16.93x | 9.30x | 10.15x |
| Cash Conversion Cycle | - | - | - | - | -3.02K | - | - | - | - | - |
| Total Non-Current Liabilities | 1.05M | 37.73M | 35.59M | 5.71M | 4.44M | 3.15M | 4.47M | 498.73M | 104.85M | 5.08M |
| Long-Term Debt | 0 | 0 | -17.21M | 0 | 0 | 0 | 0 | 494.54M | 100M | 0 |
| Capital Lease Obligations | 0 | 0 | 962K | 0 | 318.56K | 75K | 1.25M | 2.76M | 3.29M | 3.45M |
| Deferred Tax Liabilities | 945.67K | 706.22K | 3.37M | 2.2M | 1.61M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.27M | -39.87K | 5.73M | 3.28M | 2.2M | 2.51M | 3.22M | 1.43M | 1.56M | 1.63M |
| Total Liabilities | 5.62M | 51.35M | 62.4M | 22.59M | 14.34M | 23.05M | 30.09M | 537.51M | 125.26M | 46.81M |
| Total Debt | 0 | 0 | 0 | 0 | 699.64K | 465K | 2.78M | 518.76M | 106.1M | 7.22M |
| Net Debt | -23.22M | -35.08M | -28.45M | -35.23M | -49.26M | -65.95M | -69.01M | 170.16M | 34.67M | -97.64M |
| Debt / Equity | - | - | - | - | 0.01x | 0.01x | 0.03x | 4.10x | 1.37x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.41x |
| Net Debt / EBITDA | - | - | - | -4.80x | - | - | - | - | - | -5.59x |
| Interest Coverage | - | -28.84x | -22.18x | 8.69x | -695.65x | -208.60x | -306.71x | -13.55x | -5.45x | 0.04x |
| Total Equity | 30.1M | -4.37M | 13.98M | 55.8M | 61.12M | 79.45M | 83.28M | 126.65M | 77.69M | 388.75M |
| Equity Growth % | 0.33% | -1.15% | 4.2% | 2.99% | 0.1% | 0.3% | 0.05% | 0.52% | -0.39% | 4% |
| Book Value per Share | 0.51 | -0.07 | 0.21 | 0.65 | 1.86 | 1.14 | 0.90 | 0.66 | 0.13 | 0.54 |
| Total Shareholders' Equity | 30.1M | -4.37M | 13.98M | 55.8M | 61.12M | 79.45M | 83.28M | 126.65M | 77.69M | 388.75M |
| Common Stock | 873.03K | 772.47K | 1.04M | 2.1M | 3.47M | 826K | 980K | 2.11M | 7.02M | 7.38M |
| Retained Earnings | -67.43M | -92.21M | -114.51M | -99.8M | -97.61M | -214.74M | -299.55M | -378.33M | -993.26M | -1.21B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 27.29M | 25.74M | 0 | 0 | 22.03M | -3.79M | -2.2M | -1.89M | -2.45M | -2.29M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -24.47M | 15.18M | -20.79M | -35.14M | -15.56M | -48.11M | -72.59M | -41.58M | -76.76M | -142.11M |
| Operating CF Margin % | -19.1% | 5.27% | -1.19% | -0.62% | -25.44% | -55.94% | -40.13% | -59.04% | - | - |
| Operating CF Growth % | -0.43% | 1.62% | -2.37% | -0.69% | 0.56% | -2.09% | -0.51% | 0.43% | -0.85% | -0.85% |
| Net Income | -28.69M | -32.13M | -15.42M | 6.6M | -23.88M | -52.7M | -88.6M | -78.78M | -614.93M | -221.31M |
| Depreciation & Amortization | 68.36K | 72.5K | 348.2K | 1.49M | 1.39M | 2M | 2.46M | 2.51M | 2.05M | 89K |
| Stock-Based Compensation | 1.65M | 1.72M | 2.27M | 6.22M | 542.05K | 1.29M | 9.47M | 9.88M | 14.11M | 50.98M |
| Deferred Taxes | 1.79M | 4.66M | 0 | 3 | 309.13K | 583K | 326K | 0 | 0 | 0 |
| Other Non-Cash Items | -105.39K | 1.06M | 3.47M | 1.73M | 5.12M | -385K | 497K | 14.12M | 524.38M | 12.66M |
| Working Capital Changes | 811.79K | 39.79M | -11.47M | -51.18M | 955.98K | 619K | -67K | 8.62M | -2.37M | 15.48M |
| Change in Receivables | 0 | 0 | 0 | 0 | 4.63M | 212K | -1.14M | 975K | 4.53M | 535K |
| Change in Inventory | 0 | 0 | 0 | 0 | -2 | -6.61M | 3.6M | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | -997.71K | 1.64M | -1.71M | -4.13M | 2.26M | 2.02M |
| Cash from Investing | -51.27K | -100K | -7.42M | -410.52K | -265.33K | -421K | -306K | -624K | -587.77M | -205.34M |
| Capital Expenditures | -94K | -110K | -678.01K | -163.94K | -265.33K | -421K | -306K | -624K | -128K | -139K |
| CapEx % of Revenue | 0.07% | 0.04% | 0.04% | 0% | 0.43% | 0.49% | 0.17% | 0.89% | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 42.73K | 10K | 16.98K | 5.25K | 11.95K | 0 | 0 | -600 | -474.79M | -15.01M |
| Cash from Financing | 22.14M | 516.23K | 19.68M | 43.85M | 37.46M | 50.55M | 77.92M | 620.24M | 86.51M | 381.23M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -5.65M | 493.23K | -7.05M | -1.21M | 37.46M | 551K | 2.92M | 100.24M | 106.2M | 3.33M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -24.56M | 15.07M | -21.47M | -35.31M | -15.83M | -48.53M | -72.89M | -42.21M | -76.89M | -142.25M |
| FCF Margin % | -19.18% | 5.23% | -1.23% | -0.63% | -25.87% | -56.43% | -40.29% | -59.93% | - | - |
| FCF Growth % | -0.44% | 1.61% | -2.43% | -0.64% | 0.55% | -2.07% | -0.5% | 0.42% | -0.82% | -0.85% |
| FCF per Share | -0.42 | 0.24 | -0.33 | -0.41 | -0.48 | -0.70 | -0.79 | -0.22 | -0.12 | -0.20 |
| FCF Conversion (FCF/Net Income) | 1.01x | -0.71x | 0.73x | -3.56x | 0.65x | 0.91x | 0.82x | 0.53x | 0.12x | 0.64x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 85K | 0 | 10.65M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 7K | 0 | 52K | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -92.45% | -166.11% | -593.72% | 28.3% | -40.86% | -74.98% | -108.89% | -75.05% | -601.85% | -94.9% |
| Return on Invested Capital (ROIC) | -346.1% | - | - | 132.64% | -104.67% | -314.71% | -465.43% | -28.75% | -32.9% | 0.12% |
| Gross Margin | - | 100% | 99.45% | 99.96% | 77.9% | 100% | 100% | -256.99% | - | - |
| Net Margin | -1899.84% | -742.05% | -163.09% | 17.5% | -3903.43% | -6127.56% | -4897.84% | -11185.94% | - | - |
| Debt / Equity | - | - | - | - | 0.01x | 0.01x | 0.03x | 4.10x | 1.37x | 0.02x |
| Interest Coverage | - | -28.84x | -22.18x | 8.69x | -695.65x | -208.60x | -306.71x | -13.55x | -5.45x | 0.04x |
| FCF Conversion | 1.01x | -0.71x | 0.73x | -3.56x | 0.65x | 0.91x | 0.82x | 0.53x | 0.12x | 0.64x |
| Revenue Growth | -43.52% | 124.82% | 507.47% | 222.45% | -98.92% | 40.55% | 110.35% | -61.07% | -100% | - |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|
| License and Service | - | - | - | 860K | 1.81M | 4.68M |
| License and Service Growth | - | - | - | - | 110.35% | 158.60% |
| Research Collaboration Agreements | - | - | - | - | - | - |
| Research Collaboration Agreements Growth | - | - | - | - | - | - |
| Licensing agreements | - | 42.77M | 583K | - | - | - |
| Licensing agreements Growth | - | - | -98.64% | - | - | - |
| Research collaboration agreement | - | 246K | - | - | - | - |
| Research collaboration agreement Growth | - | - | - | - | - | - |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|
| Latin America | - | - | 457K | 860K | 1.81M | 705K |
| Latin America Growth | - | - | - | 88.18% | 110.35% | -61.03% |
| UNITED STATES | 25.07M | 42.27M | 126K | - | - | - |
| UNITED STATES Growth | - | 68.62% | -99.70% | - | - | - |
| Latin America1 | 42K | 499K | - | - | - | - |
| Latin America1 Growth | - | 1088.10% | - | - | - | - |
| Europe1 | 310K | 246K | - | - | - | - |
| Europe1 Growth | - | -20.65% | - | - | - | - |
Summit Therapeutics Inc. (SMMT) grew revenue by 0.0% over the past year. Growth has been modest.
Summit Therapeutics Inc. (SMMT) reported a net loss of $921.6M for fiscal year 2024.
Summit Therapeutics Inc. (SMMT) has a return on equity (ROE) of -94.9%. Negative ROE indicates the company is unprofitable.
Summit Therapeutics Inc. (SMMT) had negative free cash flow of $272.1M in fiscal year 2024, likely due to heavy capital investments.